AstraZeneca holds 8.3% stake in Innate Pharma

Innate Pharma SA filed an amended ownership report showing that AstraZeneca PLC and its wholly owned subsidiary MedImmune Limited together beneficially own 7,825,501 Ordinary Shares, including 1,565,001 shares represented by ADSs.

Accepted by SEC EDGAR 02/06/2026 - 09:48 AM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Innate Pharma SA filed an amended ownership report showing that AstraZeneca PLC and its wholly owned subsidiary MedImmune Limited together beneficially own 7,825,501 Ordinary Shares, including 1,565,001 shares represented by ADSs. This stake represents 8.3% of Innate Pharma’s Ordinary Shares, based on 93,719,323 shares outstanding as of December 31, 2025, as disclosed in a recent Form 6-K. AstraZeneca PLC and MedImmune Limited are each deemed to have sole voting and dispositive power over all shares held by MedImmune Limited, and neither the reporting entities nor their listed directors and officers have traded Innate Pharma shares in the past 60 days.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What percentage of Innate Pharma (IPHA) does AstraZeneca currently own?

AstraZeneca PLC and its subsidiary MedImmune Limited beneficially own 8.3% of Innate Pharma’s Ordinary Shares. This is based on 93,719,323 Ordinary Shares outstanding as of December 31, 2025, as reported in Innate Pharma’s Form 6-K filed on January 7, 2026.

How many Innate Pharma (IPHA) shares are held by AstraZeneca and MedImmune?

AstraZeneca PLC and MedImmune Limited beneficially own 7,825,501 Innate Pharma Ordinary Shares. This total includes 1,565,001 Ordinary Shares represented by American Depositary Shares (ADSs), all held directly by MedImmune Limited, a wholly owned subsidiary of AstraZeneca PLC.

Who has voting and dispositive power over Innate Pharma (IPHA) shares held by AstraZeneca?

AstraZeneca PLC and MedImmune Limited may each be deemed to have sole voting and dispositive power over all Innate Pharma Ordinary Shares held by MedImmune. This applies to shares held both directly as Ordinary Shares and indirectly through American Depositary Shares.

Has AstraZeneca or MedImmune traded Innate Pharma (IPHA) shares recently?

The reporting entities state that neither AstraZeneca PLC, MedImmune Limited, nor any individuals listed on their schedule have effected transactions in Innate Pharma Ordinary Shares, including those represented by ADSs, during the 60 days preceding the reported event date.

How was AstraZeneca’s 8.3% stake in Innate Pharma (IPHA) calculated?

The 8.3% ownership figure is calculated using 93,719,323 Innate Pharma Ordinary Shares outstanding as of December 31, 2025. That outstanding share count comes from Innate Pharma’s Form 6-K filed with the SEC on January 7, 2026, which the reporting persons reference.

What type of Innate Pharma (IPHA) securities are covered in this ownership report?

The report covers Innate Pharma’s Ordinary Shares with a nominal value of EUR0.05 per share. It includes both Ordinary Shares and Ordinary Shares represented by American Depositary Shares (ADSs), all of which are held directly by MedImmune Limited.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13D

Under the Securities Exchange Act of 1934

(Amendment No. 1)

Innate Pharma SA

(Name of Issuer)

Ordinary Shares, EUR0.05 nominal value per share

(Title of Class of Securities)

45781K105

(CUSIP Number)

Hannah Tattersall
Deputy Company Secretary, Eastbrook, Shaftesbury Road
Cambridge, X0, CB2 8BF
44 0 20 3749 5847

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

12/22/2025

(Date of Event Which Requires Filing of This Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

SCHEDULE 13D

CUSIP No. 45781K105

1

Name of reporting person

AstraZeneca PLC

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

OO

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

UNITED KINGDOM

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 7,825,501.00
8	Shared Voting Power 0.00
9	Sole Dispositive Power 7,825,501.00
10	Shared Dispositive Power 0.00

11

Aggregate amount beneficially owned by each reporting person

7,825,501.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

8.3 %

14

Type of Reporting Person (See Instructions)

CO

Comment for Type of Reporting Person:

(1) Note to Rows 7, 9 and 11: Represents both Ordinary Shares and Ordinary Shares in the form of American Depositary Shares ("ADSs") held directly by MedImmune Limited, a wholly-owned subsidiary of AstraZeneca PLC. AstraZeneca PLC and MedImmune Limited may each be deemed to have sole voting and dispositive power over all of the Ordinary Shares held by MedImmune Limited, whether held in the form of Ordinary Shares or ADSs. (2) Note to Row 13: Based upon 93,719,323 Ordinary Shares of the Issuer outstanding as of December 31, 2025, as reported in the Issuer's Form 6-K filed with the Securities and Exchange Commission (the "SEC") on January 7, 2026.

SCHEDULE 13D

CUSIP No. 45781K105

1

Name of reporting person

MedImmune Limited

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

OO

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

UNITED KINGDOM

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 7,825,501.00
8	Shared Voting Power 0.00
9	Sole Dispositive Power 7,825,501.00
10	Shared Dispositive Power 0.00

11

Aggregate amount beneficially owned by each reporting person

7,825,501.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

8.3 %

14

Type of Reporting Person (See Instructions)

CO

Comment for Type of Reporting Person:

(1) Note to Rows 7, 9 and 11: Represents both Ordinary Shares and Ordinary Shares in the form of ADSs held directly by MedImmune Limited, a wholly-owned subsidiary of AstraZeneca PLC. AstraZeneca PLC and MedImmune Limited may each be deemed to have sole voting and dispositive power over all of the Ordinary Shares held by MedImmune Limited, whether held in the form of Ordinary Shares or ADSs. (2) Note to Row 13: Based upon 93,719,323 Ordinary Shares of the Issuer outstanding as of December 31, 2025, as reported in the Issuer's Form 6-K filed with the SEC on January 7, 2026.

SCHEDULE 13D

Item 1.	Security and Issuer
(a)	Title of Class of Securities: Ordinary Shares, EUR0.05 nominal value per share
(b)	Name of Issuer: Innate Pharma SA
(c)	Address of Issuer's Principal Executive Offices: 117 Avenue de Luminy, BP 30191, Marseille, FRANCE , 13009.
Item 1 Comment: This Amendment No. 1 to the statement on Schedule 13D with respect to the Ordinary Shares, nominal value EUR0.05 per share, of Innate Pharma S.A., filed by the Reporting Persons on October 25, 2019 (such statement, as amended herein the "Schedule 13D"), amends the Schedule 13D as set forth herein. Except as specifically amended by this Amendment No. 1, items in the Schedule 13D remain unchanged.
Item 2.	Identity and Background
(c)	The current directors and executive officers of the Reporting Persons are set forth on Schedule I attached hereto.
Item 5.	Interest in Securities of the Issuer
(a)	AstraZeneca PLC: 7,825,501 Ordinary Shares (including 1,565,001 Ordinary Shares represented by ADSs). Represents both Ordinary Shares and Ordinary Shares in the form of ADSs held directly by MedImmune Limited, a wholly-owned subsidiary of AstraZeneca PLC. Percent of class: 8.3%. MedImmune Limited: 7,825,501 Ordinary Shares (including 1,565,001 Ordinary Shares represented by ADSs). Percent of class: 8.3%. AstraZeneca PLC and MedImmune Limited may each be deemed to have sole voting and dispositive power over all of the Ordinary Shares held by MedImmune Limited, whether held in the form of Ordinary Shares or ADSs. Percentage ownership calculated based upon 93,719,323 Ordinary Shares of the Issuer outstanding as of December 31, 2025, as reported in the Issuer's Form 6-K filed with the SEC on January 7, 2026.
(b)	See the information contained in Item 5(a), which is incorporated herein by reference.
(c)	Neither the Reporting Persons nor any of the individuals listed on Schedule I have effected any transactions in the Ordinary Shares, including Ordinary Shares represented by ADSs during the past 60 days.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

AstraZeneca PLC

Signature:	/s/ Matthew Bowden
Name/Title:	Matthew Bowden / Company Secretary
Date:	02/06/2026

MedImmune Limited

Signature:	/s/ Matthew Bowden
Name/Title:	Matthew Bowden / Director
Date:	02/06/2026